qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:9ac5d11a2a316d649ec8a304 | QAG:8ee7af7d38d36ca6c684b5a5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "However, the overall survival (OS) associated with first-line treatments is less than one year, and that associated with second-line treatments is shorter at only 6-8 months, suggesting that the chemotherapy regimens for advanced ESCC may have achieved a bottleneck ( 1... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:20862e17546d7a6df806745c","quotes":["However, the overall survival (OS) associated with first-line treatments is ... | [
"CLM:20862e17546d7a6df806745c",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10185849"
] | [
"SPAN:8c8484f09d0b47fbf9e1ca74"
] | [] | [] | {"qa_id":"QA:9ac5d11a2a316d649ec8a304","qa_group_id":"QAG:8ee7af7d38d36ca6c684b5a5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"However, the overall survival (OS) associated with first-line trea... |
QA:9e822a0beaf54994c7f388f0 | QAG:9a97b0c2e5ccab3cc55585ba | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Stage IVB ESCC patients who had failed first-line immunochemotherapy received primary tumor radiotherapy (40GY/20F)/metastatic lesions radiotherapy (30GY/10F) combined with Camrelizumab and irinotecan achieved an ORR of 40.8%, a DCR of 75.5%, with median PFS and OS of ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b8161162944e452f80336565","quotes":["Stage IVB ESCC patients who had failed first-line immunochemotherapy receive... | [
"CLM:b8161162944e452f80336565",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:ba9785b6444fe128a8f3bf11"
] | [] | [] | {"qa_id":"QA:9e822a0beaf54994c7f388f0","qa_group_id":"QAG:9a97b0c2e5ccab3cc55585ba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Stage IVB ESCC patients who had failed first-line immunochemothera... |
QA:9f090d7f6765dff3fd1b859d | QAG:721d1d22197929ec30301e56 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "This study aims to evaluate the safety and effectiveness of camrelizumab combined with chemotherapy in the neoadjuvant treatment of ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c456404a1119da266ce37773","quotes":["This study aims to investigate the safety and effectiveness of camrelizumab ... | [
"CLM:c456404a1119da266ce37773",
"CLM:271ef2ae6ac25da19ecda350"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:54a097c7a006ee757a34ec0b"
] | [] | [] | {"qa_id":"QA:9f090d7f6765dff3fd1b859d","qa_group_id":"QAG:721d1d22197929ec30301e56","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"This study aims to evaluate the safety and effectiveness of camrel... |
QA:9f4287c8da33ddb2860d454a | QAG:988d0d299a00989ede182485 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "NLR level at baseline was increased in patients with ESCC when compared with tumor-free people, therefore we calculated PLR, MLR and SII in general population to assess the influence of tumor on alteration of PLR, MLR and SII (Table 6 )"? Return the original wording wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:eaaafc170797b1cc5c31b103","quotes":["NLR level at baseline was increased in patients with ESCC when compared with... | [
"CLM:eaaafc170797b1cc5c31b103",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:e6f30feef51549f9cbe18e8f"
] | [] | [] | {"qa_id":"QA:9f4287c8da33ddb2860d454a","qa_group_id":"QAG:988d0d299a00989ede182485","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"NLR level at baseline was increased in patients with ESCC when com... |
QA:a0c0bd75925d15b483632877 | QAG:1e80fcfc2687cfe60fc7aa3b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "trial participants in the PD-1 inhibitor arm received anti-PD-1 agent only, while participants in the chemotherapy arm received conventional chemotherapy regimen; and the trial used at least three of the following (OS, progression-free survival [PFS], objective respons... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9a4481111b1828f6dbd510d4","quotes":["Studies eligible for the analyses satisfied each of the following requiremen... | [
"CLM:9a4481111b1828f6dbd510d4",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:947e310371175820538cead3"
] | [] | [] | {"qa_id":"QA:a0c0bd75925d15b483632877","qa_group_id":"QAG:1e80fcfc2687cfe60fc7aa3b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"trial participants in the PD-1 inhibitor arm received anti-PD-1 ag... |
QA:a18057de92226f2b346961ba | QAG:2134a99a2ea88e008ffa3e4a | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients received camrelizumab at different dose levels, including three, 64 and two patients receiving a dose of 60, 200 and 400 mg every 2 weeks, respectively"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requir... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:384ff643aa3419ab7398b368","quotes":["A total of 69 patients with advanced ESCC enrolled in our center were consec... | [
"CLM:384ff643aa3419ab7398b368",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9161342"
] | [
"SPAN:4d2992a79391d13bb675a64c"
] | [] | [] | {"qa_id":"QA:a18057de92226f2b346961ba","qa_group_id":"QAG:2134a99a2ea88e008ffa3e4a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients received camrelizumab at different dose levels, including... |
QA:a1b914f3749cee684c175fa2 | QAG:bb77a75506f36336c9a9b712 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Overall, a high enrichment score of the TREM2 + TAMs gene signature predicted poor OS and PFS and was associated with potential immunotherapy modulation"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4df10b4f9a49b50b91130530","quotes":["In addition, we collected 10 samples from ESCC patients treated with immunot... | [
"CLM:4df10b4f9a49b50b91130530",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:2cf2acf2640f64a604aaae7c"
] | [] | [] | {"qa_id":"QA:a1b914f3749cee684c175fa2","qa_group_id":"QAG:bb77a75506f36336c9a9b712","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Overall, a high enrichment score of the TREM2 + TAMs gene signatur... |
QA:a1dd1905b7cd35d4a88d9d74 | QAG:ee1de31f36beb0803ffa83f9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In a similar phase Ib study, 20 locally advanced ESCC patients treated with radiotherapy plus Camrelizumab achieved an ORR of 74%, with a median OS and progression-free survival (PFS) of 16.7 and 11.7 months, respectively, and 24-month OS and PFS rates of 31.6% and 35.... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fc46e1f450fd1368e6576630","quotes":["In a similar phase Ib study, 20 locally advanced ESCC patients treated with ... | [
"CLM:fc46e1f450fd1368e6576630",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:0ffcf926c03c97c271bb3d6a"
] | [] | [] | {"qa_id":"QA:a1dd1905b7cd35d4a88d9d74","qa_group_id":"QAG:ee1de31f36beb0803ffa83f9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In a similar phase Ib study, 20 locally advanced ESCC patients tre... |
QA:a48a9ca00261508490421bd5 | QAG:1422406cc9d205915e5e71ad | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The combination of PD-1 inhibitors with TP or CF improved OS compared with chemotherapy alone, and there were no significant differences between the CF group and TP group (P = 0.499), demonstrating that both chemotherapy regimens can be combined with immunotherapy for ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:57eacf04ca515b6db9964b37","quotes":["The combination of PD-1 inhibitors with TP or CF significantly improved OS c... | [
"CLM:57eacf04ca515b6db9964b37",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10185849"
] | [
"SPAN:4f392a90fe9847ca664b56e7"
] | [] | [] | {"qa_id":"QA:a48a9ca00261508490421bd5","qa_group_id":"QAG:1422406cc9d205915e5e71ad","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The combination of PD-1 inhibitors with TP or CF improved OS compa... |
QA:a5a83b6528e274263889128d | QAG:6b2503ee60171d229a2eeba2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We have previously reported that the presence of TLSs around gastric cancer is associated with a good prognosis, that increased granzyme B and perforin expression is observed around TLSs, and that memory T cells are present around TLSs"? Return the original wording wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c96b9373ac4693053d2672fe","quotes":["We have previously reported that the presence of TLSs around gastric cancer ... | [
"CLM:c96b9373ac4693053d2672fe",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:45a2a8f4c82bf35ae7a0103b"
] | [] | [] | {"qa_id":"QA:a5a83b6528e274263889128d","qa_group_id":"QAG:6b2503ee60171d229a2eeba2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We have previously reported that the presence of TLSs around gastr... |
QA:a5b543cdec61b59fb258fa5a | QAG:ea61d5bea3a3e7bf0ade721e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In recent years, several studies have reported that nCT combined with ICIs followed by esophagectomy could be recognized as an effective treatment for locally advanced ESCC, and the pCR could be increased to 25%-39.2% ( 24 – 27 )"? Return the original wording with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:801c1b16ef7c48edd1f326f3","quotes":["In recent years, several studies have reported that nCT combined with ICIs f... | [
"CLM:801c1b16ef7c48edd1f326f3",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9585292"
] | [
"SPAN:21d1aceb2c38b9749c07f3e9"
] | [] | [] | {"qa_id":"QA:a5b543cdec61b59fb258fa5a","qa_group_id":"QAG:ea61d5bea3a3e7bf0ade721e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In recent years, several studies have reported that nCT combined w... |
QA:a8e469da8f1134823c0637be | QAG:f7e691d45534acf8f8bbf844 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Nevertheless, in our cohort of patients, the neoadjuvant setting, camrelizumab combined with chemotherapy led to good survival outcomes, as well as high rates of MPR and pCR, among patients with locally advanced ESCC"? Return the original wording with paper, Claim, and... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b0325298176d99156af0d2a1","quotes":["Nevertheless, in our cohort of patients, the neoadjuvant setting, camrelizum... | [
"CLM:b0325298176d99156af0d2a1",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9251418"
] | [
"SPAN:9ff32b37d3cc9eaebf333ee9"
] | [] | [] | {"qa_id":"QA:a8e469da8f1134823c0637be","qa_group_id":"QAG:f7e691d45534acf8f8bbf844","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Nevertheless, in our cohort of patients, the neoadjuvant setting, ... |
QA:a985487267f9d8df1eed0484 | QAG:64ae336d88fca3670a7fe7d7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients and Methods Patients with LA-ESCC who received nICT followed by surgery from Jun 2019 to Dec 2021 were enrolled and randomly divided into two sets (7:3)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e44c1161a94a0c69b1e2a4bd","quotes":["Patients and Methods Patients with LA-ESCC who received nICT followed by sur... | [
"CLM:e44c1161a94a0c69b1e2a4bd",
"CLM:08adec9d2dfaf31bc5d24f84"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:e122466691681ae1b0194be5"
] | [] | [] | {"qa_id":"QA:a985487267f9d8df1eed0484","qa_group_id":"QAG:64ae336d88fca3670a7fe7d7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients and Methods Patients with LA-ESCC who received nICT follo... |
QA:aca4dd1434484901a00f6618 | QAG:d7c84f0d4c2fa40d0adf6727 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Despite the TCGA database showing that high TREM2 , SPP1 , APOE , C1QC , C1QB , and C1QA expression led to poor OS, the roles of these genes in ESCC remain unclear"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4eb5bcb0a874c4f497a78fb7","quotes":["Despite the TCGA database showing that high TREM2 , SPP1 , APOE , C1QC , C1Q... | [
"CLM:4eb5bcb0a874c4f497a78fb7",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:4462886dc46ef8fdb066f973"
] | [] | [] | {"qa_id":"QA:aca4dd1434484901a00f6618","qa_group_id":"QAG:d7c84f0d4c2fa40d0adf6727","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Despite the TCGA database showing that high TREM2 , SPP1 , APOE , ... |
QA:ad865a4dfe49319b20daf49b | QAG:11bb4096e9a47fff0d347b72 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For locally advanced resectable ESCC, adding immunotherapy to standard care of the neoadjuvant chemoradiotherapy followed by surgery has not increased the pCR rate but has increased toxicity to some extent"? Return the original wording with paper, Claim, and Evidence S... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c0099aca0f18af9f125b355a","quotes":["For locally advanced resectable ESCC, adding immunotherapy to standard care ... | [
"CLM:c0099aca0f18af9f125b355a",
"CLM:2a0dc33e26036765ea69bb10"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:5296239b0e6a815d33da6e01"
] | [] | [] | {"qa_id":"QA:ad865a4dfe49319b20daf49b","qa_group_id":"QAG:11bb4096e9a47fff0d347b72","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For locally advanced resectable ESCC, adding immunotherapy to stan... |
QA:ae498ce8078c70804edf1cb0 | QAG:8617bedf0fa0ccd0c5f913ff | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "All patients were histologically confirmed locally advanced ESCC, which was defined as cT1N1-3M0 or cT2-4aN0-3M0 (AJCC, 8th Edition) based on contrast increased computerized tomography (CT), and/or magnetic resonance imaging (MRI), upper gastrointestinal endoscopic ult... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:671d39d28baa1cfc8030adf3","quotes":["All patients were histologically confirmed locally advanced ESCC, which was ... | [
"CLM:671d39d28baa1cfc8030adf3",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9251418"
] | [
"SPAN:9d9c627691ae94061e02ed09"
] | [] | [] | {"qa_id":"QA:ae498ce8078c70804edf1cb0","qa_group_id":"QAG:8617bedf0fa0ccd0c5f913ff","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"All patients were histologically confirmed locally advanced ESCC, ... |
QA:b21e7e3351bec5872e9bf096 | QAG:e3b0c5281e866e96a7601487 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared with chemotherapy alone, chemo-immunotherapy improved the OS of ESCC patients (pooled HR=0.69; 95% CI, 0.63–0.76; p<0.01)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5b77bb88a4c4a4e3059b6c01","quotes":["Compared with chemotherapy alone, chemo-immunotherapy significantly improved... | [
"CLM:5b77bb88a4c4a4e3059b6c01",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:68d4829f62eab273c5d5ad1f"
] | [] | [] | {"qa_id":"QA:b21e7e3351bec5872e9bf096","qa_group_id":"QAG:e3b0c5281e866e96a7601487","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared with chemotherapy alone, chemo-immunotherapy improved the... |
QA:b38218a7c8d5325ca3d81fea | QAG:14dfeb08495136e977309204 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "This study aims to evaluate the prediction efficacy of pre-therapeutic CT imaging based radiomics models in treatment response of patients with advanced ESCC receiving anti-PD-1 antibodies plus chemotherapy"? Return the original wording with paper, Claim, and Evidence ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:350aa98892765ca25e7ae951","quotes":["This study aimed to evaluate the prediction efficacy of pre-therapeutic CT i... | [
"CLM:350aa98892765ca25e7ae951",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8557514"
] | [
"SPAN:32049d0c34b0b26f3650b2f3"
] | [] | [] | {"qa_id":"QA:b38218a7c8d5325ca3d81fea","qa_group_id":"QAG:14dfeb08495136e977309204","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"This study aims to evaluate the prediction efficacy of pre-therape... |
QA:b41559bff24bf6ec379fad74 | QAG:e09c2f21ac284cfcb59ffc64 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Conclusion Second line PD-1 inhibitors improved the OS and ORR of patients with advanced ESCC, especially the OS of those with positive PD-L1 expression, and did not result in significant improvement in PFS and DCR"? Return the original wording with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c58065dc07a58847e1d42e76","quotes":["Conclusion Second line PD-1 inhibitors significantly improved the OS and ORR... | [
"CLM:c58065dc07a58847e1d42e76",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:c23a41e97b0ea1be5992225a"
] | [] | [] | {"qa_id":"QA:b41559bff24bf6ec379fad74","qa_group_id":"QAG:e09c2f21ac284cfcb59ffc64","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Conclusion Second line PD-1 inhibitors improved the OS and ORR of ... |
QA:b45656ba1707ea3f46f7eff9 | QAG:1b1e141b188bb3906e796846 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Several studies have shown that PD-1 inhibitors plus chemotherapy prolonged survival for patients with advanced ESCC ( 20 – 25 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact support... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:230010b55d8fa314c138f186","quotes":["Several studies have shown that PD-1 inhibitors plu... | [
"CLM:230010b55d8fa314c138f186",
"CLM:08a48a247c9286d56048a968",
"CLM:47163ecffcf8a1593d4b37fa"
] | [
"PMCID:PMC9098952",
"PMCID:PMC9428701"
] | [
"SPAN:67602ea38a816048a7f33d05",
"SPAN:41a424d8ad80b9cfb678d3be"
] | [
"ASC2:22dae31d277080756ef7b9f8"
] | [] | {"qa_id":"QA:b45656ba1707ea3f46f7eff9","qa_group_id":"QAG:1b1e141b188bb3906e796846","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Several studies have shown that PD-1 inhibitors plus chemotherapy ... |
QA:b5db57a22165df0552e2c173 | QAG:a263a5be86d6f0d6e5c56dff | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "This study aims to evaluate the efficacy and safety of immune checkpoint inhibitor treatment in esophageal squamous cell carcinoma"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7491c210b1a002a124d5e6d1","quotes":["This study aimed to investigate the efficacy and safety of immune checkpoint... | [
"CLM:7491c210b1a002a124d5e6d1",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8724211"
] | [
"SPAN:9c6abce7ecd59cd02c0f3022"
] | [] | [] | {"qa_id":"QA:b5db57a22165df0552e2c173","qa_group_id":"QAG:a263a5be86d6f0d6e5c56dff","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"This study aims to evaluate the efficacy and safety of immune chec... |
QA:b6395bb21a2ae65175261293 | QAG:4a4bc47735d02f8342f1cd5b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The clinical proteomic tumor analysis consortium (CPTAC) data also suggest that decreased protein level of β ‐TrCP exists in other cancer types, including breast invasive carcinoma, colon adenocarcinoma, and glioblastoma (GBM) (Figure S1A , Supporting Information)"? Re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ed1b1ec661f1edc4c89a9c65","quotes":["However, at the protein level, β ‐TrCP expressed at lower level in ESCC tiss... | [
"CLM:ed1b1ec661f1edc4c89a9c65",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:b9884cc81b334539931e7f81"
] | [] | [] | {"qa_id":"QA:b6395bb21a2ae65175261293","qa_group_id":"QAG:4a4bc47735d02f8342f1cd5b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The clinical proteomic tumor analysis consortium (CPTAC) data also... |
QA:ba395eb91b4e90b798c2d9d9 | QAG:aea098746e70212e068b062f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "668 § Normal albumin, n (%) 64 (100%) 32 (100%) 32 (100%) NA increased leucocyte, n (%) 10 (15.6%) 5 (15.6%) 5 (15.6%) 1.000 † C-reactive protein≥10 mg/L, n (%) 31 (48.4%) 13 (40.6%) 18 (56.3%) 0.211 † Underlying diseases, n (%) 21 (32.8%) 10 (31.3%) 11 (34.4%) 0.790 †... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dea79c43110a5a8fc7728e6d","quotes":["Table 1 Clinicopathological characteristics of advanced ESCC patients treate... | [
"CLM:dea79c43110a5a8fc7728e6d",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8557514"
] | [
"SPAN:ea273b8d1fac66e5d6f1eb24"
] | [] | [] | {"qa_id":"QA:ba395eb91b4e90b798c2d9d9","qa_group_id":"QAG:aea098746e70212e068b062f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"668 § Normal albumin, n (%) 64 (100%) 32 (100%) 32 (100%) NA incre... |
QA:bcad7a7ac135ced55a6d17d9 | QAG:7bb5d953e7842e9e7d641828 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "These changes have led to prolonged survival for ESCC patients, but questions remain which are challenging to answer in the context of single trial datasets"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requiremen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:53533c49ce570418a2807de9","quotes":["These changes have led to prolonged survival for ESCC patients, but question... | [
"CLM:53533c49ce570418a2807de9",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8804258"
] | [
"SPAN:cd9d323d7f56ea39ad2ef6f2"
] | [] | [] | {"qa_id":"QA:bcad7a7ac135ced55a6d17d9","qa_group_id":"QAG:7bb5d953e7842e9e7d641828","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"These changes have led to prolonged survival for ESCC patients, bu... |
QA:bd74bb1ddc78725268f529fd | QAG:7e8853f76e3e0321b891004d | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In ESCC patient‐derived xenograft (PDX) models, the inhibitory effect of ATRA on tumor growth was also observed, and the level of OTUD6B was correlated with β ‐TrCP and negatively correlated with SNAIL (Figure 6G,H and Figure S6B , Supporting Information)"? Return the ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9e570f363a68574a554557c5","quotes":["In ESCC patient‐derived xenograft (PDX) models, the inhibitory effect of ATR... | [
"CLM:9e570f363a68574a554557c5",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:ab04ebf758c90278df9985d0"
] | [] | [] | {"qa_id":"QA:bd74bb1ddc78725268f529fd","qa_group_id":"QAG:7e8853f76e3e0321b891004d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In ESCC patient‐derived xenograft (PDX) models, the inhibitory eff... |
QA:be947e65e7ef2536223eefe3 | QAG:e1c41e0024a8f9e74f0d0d13 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "11 However, there is a lack of studies regarding risk factors of pCR prediction in LA-ESCC patients who received nICT"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:baa29850fac2c86a8ababd41","quotes":["11 However, there is a lack of studies regarding risk factors of pCR predict... | [
"CLM:baa29850fac2c86a8ababd41",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:e6ff29ec276de32cbf7b2348"
] | [] | [] | {"qa_id":"QA:be947e65e7ef2536223eefe3","qa_group_id":"QAG:e1c41e0024a8f9e74f0d0d13","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"11 However, there is a lack of studies regarding risk factors of p... |
QA:bf36aa69aae577eee9650ad9 | QAG:1d1132cac030b9c3a48100bd | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients with advanced ESCC who received second or further-line treatment of anlotinib plus PD-1 blockade were grouped as cohort A (n=48), and those who received anlotinib monotherapy were grouped as cohort B (n=50)"? Return the original wording with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:47163ecffcf8a1593d4b37fa","quotes":["Patients with advanced ESCC who received second or further-line treatment of... | [
"CLM:47163ecffcf8a1593d4b37fa",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9428701"
] | [
"SPAN:41a424d8ad80b9cfb678d3be"
] | [] | [] | {"qa_id":"QA:bf36aa69aae577eee9650ad9","qa_group_id":"QAG:1d1132cac030b9c3a48100bd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients with advanced ESCC who received second or further-line tr... |
QA:bf4cc50971801cf8f424f8cd | QAG:c0b8a273f856f29ab145f569 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For locally advanced unresectable ESCC, the addition of immunotherapy to definitive chemoradiotherapy during the concurrent or consolidation phase holds promise for improved long-term survival"? Return the original wording with paper, Claim, and Evidence Span reference... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:08adec9d2dfaf31bc5d24f84","quotes":["For locally advanced unresectable ESCC, the addition of immunotherapy to def... | [
"CLM:08adec9d2dfaf31bc5d24f84",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:d02eaa88bf26fc37054d90ff"
] | [] | [] | {"qa_id":"QA:bf4cc50971801cf8f424f8cd","qa_group_id":"QAG:c0b8a273f856f29ab145f569","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For locally advanced unresectable ESCC, the addition of immunother... |
QA:c07518d8a60c15fb6947848f | QAG:24c377e5efc5fa4666f6b20b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The ESCORT randomized phase 3 study ( 14 ) showed that camrelizumab improved OS compared with chemotherapy as second-line therapy in Chinese patients with advanced ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenanc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:81072385b58f887727eb7b87","quotes":["The ESCORT randomized phase 3 study ( 14 ) showed that camrelizumab improved... | [
"CLM:81072385b58f887727eb7b87",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8724211"
] | [
"SPAN:f002ae18d11a642e817fcd85"
] | [] | [] | {"qa_id":"QA:c07518d8a60c15fb6947848f","qa_group_id":"QAG:24c377e5efc5fa4666f6b20b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The ESCORT randomized phase 3 study ( 14 ) showed that camrelizuma... |
QA:c1f173cd2b984a9ccdf21eb6 | QAG:029adb4d4b03aca22c19130e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:88412ad9eca53f00a28e6610","quotes":["Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal s... | [
"CLM:88412ad9eca53f00a28e6610",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:942cbe17a04187abc18f3259"
] | [] | [] | {"qa_id":"QA:c1f173cd2b984a9ccdf21eb6","qa_group_id":"QAG:029adb4d4b03aca22c19130e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Moreover, co-culturing of PBMCs with an anticancer drug-treated es... |
QA:c2a743fb9c6b69d9feac87d0 | QAG:729b2ee844e125ec45ec4760 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared with chemotherapy alone, the incorporation of anti-programmed cell death-1 (PD-1) antibodies into chemotherapy has improved the prognosis of ESCC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b95eb0dee0b66b44200ff790","quotes":["Compared with chemotherapy alone, the incorporation of anti-programmed cell ... | [
"CLM:b95eb0dee0b66b44200ff790",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:0ac47b6461f852f718fc1878"
] | [] | [] | {"qa_id":"QA:c2a743fb9c6b69d9feac87d0","qa_group_id":"QAG:729b2ee844e125ec45ec4760","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared with chemotherapy alone, the incorporation of anti-progra... |
QA:c3fa462bbee57da530d85c5b | QAG:f87f18f4149df99e934a71bb | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In addition, adjuvant nivolumab improved disease-free survival (22.4 versus 11.0 months, hazard ratio (HR) 0.69) in esophageal cancer patients who received nCRT but had residual disease at the time of resection in the CheckMate-577 trial, with the greatest benefit seen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f2133e79e163974bbccfe48d","quotes":["In addition, adjuvant nivolumab significantly improved disease-free survival... | [
"CLM:f2133e79e163974bbccfe48d",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC10427424"
] | [
"SPAN:b7d6012ae5ec4dbb4d96d43a"
] | [] | [] | {"qa_id":"QA:c3fa462bbee57da530d85c5b","qa_group_id":"QAG:f87f18f4149df99e934a71bb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In addition, adjuvant nivolumab improved disease-free survival (22... |
QA:c4f88fdc0b7b9876a7ec671e | QAG:b812a8b0c0f7e86009e0038b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "7%) in advanced ESCC was higher than that of cohort B (47.9%) (P=0.019)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span referenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8ffb7935cf6b3147dd217875","quotes":["The DCR of cohort A (71.7%) in advanced ESCC was higher than that of cohort ... | [
"CLM:8ffb7935cf6b3147dd217875",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9428701"
] | [
"SPAN:749f028f23a7eac4fa430df4"
] | [] | [] | {"qa_id":"QA:c4f88fdc0b7b9876a7ec671e","qa_group_id":"QAG:b812a8b0c0f7e86009e0038b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"7%) in advanced ESCC was higher than that of cohort B (47.9%) (P=0... |
QA:c5ea6004ac005fd147ecfd2a | QAG:84511ab9862e8a30a097707f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Overexpression of CD73 promotes the malignant properties of cancers, such as proliferation, invasion, migration, adhesion, and metastasis, and it was associated with specific clinical characteristics and worse prognosis in many types of human cancers, including melanom... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:75a6b1c4de8ba26fc050e167","quotes":["Overexpression of CD73 promotes the malignant properties of cancers, such as... | [
"CLM:75a6b1c4de8ba26fc050e167",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:1b7b3fba0d4b71eec2d3373d"
] | [] | [] | {"qa_id":"QA:c5ea6004ac005fd147ecfd2a","qa_group_id":"QAG:84511ab9862e8a30a097707f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Overexpression of CD73 promotes the malignant properties of cancer... |
QA:c6cc1522619ba38a618c4743 | QAG:1796f85a55830246e7129528 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared with chemotherapy alone, our pooled analysis showed that the incidence rates of adverse effects were not significantly increased in ESCC patients who received chemo-immunotherapy, suggesting chemo-immunotherapy was a kind of treatment with high efficacy and sa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:76e8a16af42dadb52dd2bcfd","quotes":["Compared with chemotherapy alone, our pooled analysis showed that the incide... | [
"CLM:76e8a16af42dadb52dd2bcfd",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:b7732c3db7dcef78052cd131"
] | [] | [] | {"qa_id":"QA:c6cc1522619ba38a618c4743","qa_group_id":"QAG:1796f85a55830246e7129528","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared with chemotherapy alone, our pooled analysis showed that ... |
QA:cb559601d9d00f98c5da8dcc | QAG:7e09260adb103b3b06e5a348 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Background In view of the fact that peripheral blood parameters have been reported as predictors of immunotherapy to various cancers, this study aims to evaluate the predictors of response to anti-programmed death-1 (anti-PD-1) therapy in patients with esophageal squam... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:31e848ae4221bd6fe6d69b90","quotes":["Background In view of the fact that peripheral blood parameters have been re... | [
"CLM:31e848ae4221bd6fe6d69b90",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:db93ed8cdeb25d81c28d514f"
] | [] | [] | {"qa_id":"QA:cb559601d9d00f98c5da8dcc","qa_group_id":"QAG:7e09260adb103b3b06e5a348","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Background In view of the fact that peripheral blood parameters ha... |
QA:cdee4ff3ee4ca21340a57fb0 | QAG:f8b01aa8a02cc85c9a124ab6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients with resectable LA-ESCC who received nICT followed by surgery from Jun 2019 to Dec 2021 were identified in the database of our department"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3f38aee9db16d218c660a1b8","quotes":["Patients with resectable LA-ESCC who received nICT followed by surgery from ... | [
"CLM:3f38aee9db16d218c660a1b8",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:3b2825a94e4cff8a9b1a92de"
] | [] | [] | {"qa_id":"QA:cdee4ff3ee4ca21340a57fb0","qa_group_id":"QAG:f8b01aa8a02cc85c9a124ab6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients with resectable LA-ESCC who received nICT followed by sur... |
QA:cecaf5c8bf92ccbc3778ca58 | QAG:040ebe80ba036806bba7f096 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Although immunotherapy alone did not improve PFS, the superior OS suggested that immunotherapy was also a good option for patients with ESCC who were refractory or intolerant to chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:67fed3a1e4ff970b39ad5a74","quotes":["Although immunotherapy alone did not improve PFS, the superior OS suggested ... | [
"CLM:67fed3a1e4ff970b39ad5a74",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10185849"
] | [
"SPAN:fea593236473e275184604ac"
] | [] | [] | {"qa_id":"QA:cecaf5c8bf92ccbc3778ca58","qa_group_id":"QAG:040ebe80ba036806bba7f096","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Although immunotherapy alone did not improve PFS, the superior OS ... |
QA:d1307a1d641d6d72f17d0792 | QAG:9758a76851b42d1d456f361f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro (Fig. 6 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:895d066fa589bfffc6a1abc1","quotes":["Co-culturing of PBMCs with an anticancer drug-treated esophageal squamous ce... | [
"CLM:895d066fa589bfffc6a1abc1",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:5e8d6b7ede1cc0b2c8510b1a"
] | [] | [] | {"qa_id":"QA:d1307a1d641d6d72f17d0792","qa_group_id":"QAG:9758a76851b42d1d456f361f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Co-culturing of PBMCs with an anticancer drug-treated esophageal s... |
QA:d1d0e8ac26b9d8512b428586 | QAG:c758c5c4abaf1c637bbda054 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 64 patients with advance inoperable ESCC receiving 200 mg every 3 weeks of Sintilimab plus Docetaxel (60 mg/m 2 ) and Carboplatin (AUC = 5) at two centers between January 2019 and June 2020 were included in this study approved by the two institutional review... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:02001ad96144c794bcc3e9a5","quotes":["A total of 64 patients with advance inoperable ESCC... | [
"CLM:02001ad96144c794bcc3e9a5",
"CLM:08a48a247c9286d56048a968",
"CLM:ba4f6489aaeb1263201db7e0",
"CLM:11a8bd68e85fd714329111fe",
"CLM:920eeff9e0fea211b0935088"
] | [
"PMCID:PMC8557514",
"PMCID:PMC9606329",
"PMCID:PMC8262036"
] | [
"SPAN:d248e03a9c0effcd8331ba03",
"SPAN:d8fb2eb9246a7d330a888edb",
"SPAN:72099f17d508c1f9bf2adb05",
"SPAN:91fcf26088ed4609657329a5"
] | [
"ASC2:d6a1d7a195e23269d8bec94c",
"ASC2:b0e5062d16e7b6fc01dbc769"
] | [
"HYP:DCH:bd6169127d9bf71668e2277d"
] | {"qa_id":"QA:d1d0e8ac26b9d8512b428586","qa_group_id":"QAG:c758c5c4abaf1c637bbda054","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 64 patients with advance inoperable ESCC receiving 200 ... |
QA:d241a16b9ca0457c9db1f929 | QAG:69f16a63e3458daa3d827ef4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Similarly, for validation, the ‘IFN/EMT score’ was further shown to be associated with clinical benefits in a variety of advanced disease types (for example, metastatic urothelial cancer, melanoma, gastric cancer and nonsmall cell lung cancer) in patients who received ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8d51e75824136c5b52f08ec8","quotes":["Similarly, for validation, the ‘IFN/EMT score’ was further shown to be assoc... | [
"CLM:8d51e75824136c5b52f08ec8",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10427424"
] | [
"SPAN:5edf79a545dfd64efb655eef"
] | [] | [] | {"qa_id":"QA:d241a16b9ca0457c9db1f929","qa_group_id":"QAG:69f16a63e3458daa3d827ef4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Similarly, for validation, the ‘IFN/EMT score’ was further shown t... |
QA:d262a0cae265295172358a52 | QAG:20c179c2be4404ff2c73a803 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Table 4 Characteristics of 38 ESCC patients who received pembrolizumab/nivolumab as second-line or later treatment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8a5552ecce204ea2c512fcc7","quotes":["Table 4 Characteristics of 38 ESCC patients who received pembrolizumab/nivol... | [
"CLM:8a5552ecce204ea2c512fcc7",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:910e800fd9ba00ed46ce3972"
] | [] | [] | {"qa_id":"QA:d262a0cae265295172358a52","qa_group_id":"QAG:20c179c2be4404ff2c73a803","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Table 4 Characteristics of 38 ESCC patients who received pembroliz... |
QA:d28461783a9ae5ed2b4f051b | QAG:0b49ed3b1e6eddd378f50c5f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In addition, KEYNOTE‐590 trial presented the incidence of the TRAEs and TRM for EAC and ESCC, which were included in the meta‐analysis considering that adverse events were mostly multiorgan systemic"? Return the original wording with paper, Claim, and Evidence Span ref... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fcf7b244357569db61b96223","quotes":["In addition, KEYNOTE‐590 trial presented the incidence of the TRAEs and TRM ... | [
"CLM:fcf7b244357569db61b96223",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:5b949223ce46ecc281511a79"
] | [] | [] | {"qa_id":"QA:d28461783a9ae5ed2b4f051b","qa_group_id":"QAG:0b49ed3b1e6eddd378f50c5f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In addition, KEYNOTE‐590 trial presented the incidence of the TRAE... |
QA:d3b7d1bcc69b5004dc3ab9d8 | QAG:9cad9e6ab5ba5bf3fdb00aa2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients and methods Three hundred and forty Asian patients with advanced/metastatic ESCC were enrolled in KEYNOTE-181, including the China cohort"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:59a2633333886af10f76673c","quotes":["Patients and methods Three hundred and forty Asian patients with advanced/me... | [
"CLM:59a2633333886af10f76673c",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8764510"
] | [
"SPAN:b87ae35c27747430318ac337"
] | [] | [] | {"qa_id":"QA:d3b7d1bcc69b5004dc3ab9d8","qa_group_id":"QAG:9cad9e6ab5ba5bf3fdb00aa2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients and methods Three hundred and forty Asian patients with a... |
QA:d4a98dc6ae44ce542ce6a887 | QAG:f97c8b43e11311438bc0ce59 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Pretreatment IINS was an independent predictor for pCR in LA-ESCC patients who received nICT"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cfe060b18ee449c8e294ac68","quotes":["Pretreatment IINS was an independent predictor for pCR in LA-ESCC patients w... | [
"CLM:cfe060b18ee449c8e294ac68",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:bf58dbdc4bc95df087802cbf"
] | [] | [] | {"qa_id":"QA:d4a98dc6ae44ce542ce6a887","qa_group_id":"QAG:f97c8b43e11311438bc0ce59","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Pretreatment IINS was an independent predictor for pCR in LA-ESCC ... |
QA:d4df24148ef66834cddff3b4 | QAG:88629aa425e48402eff1d2a7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "From July 2019 to March 2021, 47 patients with esophageal squamous cell carcinoma were enrolled in Jiangsu Tumor Hospital affiliated with Nanjing Medical University, and 45 patients underwent surgery ( Figure 1 )"? Return the original wording with paper, Claim, and Evi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:df21256bc8d0c316ba325ee1","quotes":["From July 2019 to March 2021, 47 patients with esophageal squamous cell carc... | [
"CLM:df21256bc8d0c316ba325ee1",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9606329"
] | [
"SPAN:ee4a0cde2bfb0a72aca88aa0"
] | [] | [] | {"qa_id":"QA:d4df24148ef66834cddff3b4","qa_group_id":"QAG:88629aa425e48402eff1d2a7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"From July 2019 to March 2021, 47 patients with esophageal squamous... |
QA:d57ef0d7315f51aa3eeaa795 | QAG:5ed02848a5bb0b01e6ecdbb0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Figure 3 Pooled OS rates (A) and PFS rates (B) for the ICIs+TP and ICIs+FP groups among ESCC patients who received chemo-immunotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bc44c9b0b918898f03e21725","quotes":["Figure 3 Pooled OS rates (A) and PFS rates (B) for the ICIs+TP and ICIs+FP g... | [
"CLM:bc44c9b0b918898f03e21725",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:f4b26792fc67d2fcd69f5ea6"
] | [] | [] | {"qa_id":"QA:d57ef0d7315f51aa3eeaa795","qa_group_id":"QAG:5ed02848a5bb0b01e6ecdbb0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Figure 3 Pooled OS rates (A) and PFS rates (B) for the ICIs+TP and... |
QA:d5a34a9b34eff829cf120df1 | QAG:af689b35c37604ad2ada9443 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In the present study, we initially constructed and verified a novel score of IINS based on various pretreatment inflammatory and nutritional indexes to predict pCR in patients with LA-ESCC who received nICT"? Return the original wording with paper, Claim, and Evidence ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:271ef2ae6ac25da19ecda350","quotes":["In the present study, we initially constructed and verified a novel score of... | [
"CLM:271ef2ae6ac25da19ecda350",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:02842174876e5fe67b2375be"
] | [] | [] | {"qa_id":"QA:d5a34a9b34eff829cf120df1","qa_group_id":"QAG:af689b35c37604ad2ada9443","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In the present study, we initially constructed and verified a nove... |
QA:d5c15e3e60f5b6e1af86ba70 | QAG:84acdf56e1ef4528f14111dd | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "however, there were no statistical differences of PFS and OS between patients with CPS < 10 who received immunotherapy plus chemotherapy and chemotherapy alone"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance require... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bc206482682b21b126599c24","quotes":["Another phase III study that focused on ESCC, KEYNOTE-590, showed that ESCC ... | [
"CLM:bc206482682b21b126599c24",
"CLM:0313c682e9e59efb742366b7"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:e2e43868d1702bd797c7ec18"
] | [] | [] | {"qa_id":"QA:d5c15e3e60f5b6e1af86ba70","qa_group_id":"QAG:84acdf56e1ef4528f14111dd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"however, there were no statistical differences of PFS and OS betwe... |
QA:d6ecd766be1115339462f6d2 | QAG:76e8604216b9635d12cf427e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "scRNA-seq analysis demonstrated that TREM2 + TAMs was associated with immunosuppressive TME in ESCC and immunotherapy modulation"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact support... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f3c65ed6f298e4cc07f7ca9f","quotes":["3.5. scRNA-seq analysis demonstrated that TREM2 + TAMs were associated with ... | [
"CLM:f3c65ed6f298e4cc07f7ca9f",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:886e1551f6cf9a85dd59d05c"
] | [] | [] | {"qa_id":"QA:d6ecd766be1115339462f6d2","qa_group_id":"QAG:76e8604216b9635d12cf427e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"scRNA-seq analysis demonstrated that TREM2 + TAMs was associated w... |
QA:d75fc3a1f8d6dcc6c5accb94 | QAG:7e72ad61c7222bd94fe1a090 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In the context of adjuvant therapy for resectable ESCC, the randomized, double-blind, placebo-controlled phase III CheckMate 577 study demonstrated that 1-year adjuvant Nivolumab prolonged disease-free survival (DFS) (22.4m vs 11.0 m) and OS (29.7m vs 11.0m) in postope... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0f87746737e3f4978976c066","quotes":["3.1.2. In the context of adjuvant therapy for resectable ESCC, the randomize... | [
"CLM:0f87746737e3f4978976c066",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:cd067fe1f29a96785ca322fd"
] | [] | [] | {"qa_id":"QA:d75fc3a1f8d6dcc6c5accb94","qa_group_id":"QAG:7e72ad61c7222bd94fe1a090","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In the context of adjuvant therapy for resectable ESCC, the random... |
QA:d7835f72de29e246f4f500dd | QAG:0cd9651c2a3072cd004c0d73 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "These changes have led to prolonged survival for ESCC patients, but questions remain which are challenging to answer in the context of single trial datasets"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requiremen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f662a3e162951dc2e9f8efb5","quotes":["These changes have led to prolonged survival for ESCC patients, but question... | [
"CLM:f662a3e162951dc2e9f8efb5",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8804258"
] | [
"SPAN:cd9d323d7f56ea39ad2ef6f2"
] | [] | [] | {"qa_id":"QA:d7835f72de29e246f4f500dd","qa_group_id":"QAG:0cd9651c2a3072cd004c0d73","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"These changes have led to prolonged survival for ESCC patients, bu... |
QA:d7e3b20639a20465147fae09 | QAG:556e686a1aae83cf4da75339 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Inclusion criteria were included patients with locally advanced resectable stage ESCC; the disease was histopathologically confirmed in tissue samples; receiving simple nCT or plus ICIs following esophagectomy; at least one of the following primary outcomes were report... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3854cbb573dcd1d4a85c0b97","quotes":["Inclusion criteria were included: patients with locally advanced resectable ... | [
"CLM:3854cbb573dcd1d4a85c0b97",
"CLM:4df10b4f9a49b50b91130530"
] | [
"PMCID:PMC9585292"
] | [
"SPAN:80db3f8a184bb3e9ed8b0f3b"
] | [] | [] | {"qa_id":"QA:d7e3b20639a20465147fae09","qa_group_id":"QAG:556e686a1aae83cf4da75339","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Inclusion criteria were included patients with locally advanced re... |
QA:d8112901f600ef30dc4488f4 | QAG:2c63498fe58959d3a42e9c10 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In our meta-analysis, second-line PD-1 blockade decreased the risk of death by 27% in patients with advanced ESCC when comparing conventional chemotherapy (HR = 0.73, P < 0.001)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:315ada46466f55c23a6eebfd","quotes":["In our meta-analysis, second-line PD-1 blockade decreased the risk of death ... | [
"CLM:315ada46466f55c23a6eebfd",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:cb3eb11dcc5be174e3240ed1"
] | [] | [] | {"qa_id":"QA:d8112901f600ef30dc4488f4","qa_group_id":"QAG:2c63498fe58959d3a42e9c10","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In our meta-analysis, second-line PD-1 blockade decreased the risk... |
QA:db124aa3bbcd46a49c340236 | QAG:b9cea559e24ae223dd968f54 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We further validated the predictive power of molecular subtypes in an independent cohort of 36 Chinese ESCC patients who had received PD-1/PD-L1 therapy in combination with chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Int... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4fbb69ca29a1a59e5e60050a","quotes":["We further validated the predictive power of molecular subtypes in an indepe... | [
"CLM:4fbb69ca29a1a59e5e60050a",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9599230"
] | [
"SPAN:e9cedaf3a496db11093c6bcd"
] | [] | [] | {"qa_id":"QA:db124aa3bbcd46a49c340236","qa_group_id":"QAG:b9cea559e24ae223dd968f54","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We further validated the predictive power of molecular subtypes in... |
QA:db165e142a50c607acb50acd | QAG:1bf02e6d8344642da9b025d0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "3% of the ESCC patients who received chemo-immunotherapy discontinued treatment because of adverse effects ( 11 – 14 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passag... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9a888157ae40be5a3a88bd51","quotes":["It has been reported that 11.7%-45.3% of the ESCC patients who received chem... | [
"CLM:9a888157ae40be5a3a88bd51",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:430fa75d2a9bb16e0d5c2a28"
] | [] | [] | {"qa_id":"QA:db165e142a50c607acb50acd","qa_group_id":"QAG:1bf02e6d8344642da9b025d0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"3% of the ESCC patients who received chemo-immunotherapy discontin... |
QA:dc201405ecdba5fc79f0496f | QAG:6502e671077f2b60f340fae4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 10 articles (1688 ESCC patients) were included in the final analysis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9a1e8a74c28d7fc91ec33476","quotes":["A total of 10 articles (1688 ESCC patients) were included in the final analy... | [
"CLM:9a1e8a74c28d7fc91ec33476",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:cab40c5448d93b025e65cb24"
] | [] | [] | {"qa_id":"QA:dc201405ecdba5fc79f0496f","qa_group_id":"QAG:6502e671077f2b60f340fae4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 10 articles (1688 ESCC patients) were included in the f... |
QA:dd7ad13a56fc2fda239fc839 | QAG:a7f097c876c56340661c7940 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Moreover, the transwell assay revealed knockdown of CD73 in two ESCC cell lines, TE1 and KYSE30, exhibited decreased abilities of cell invasion and migration"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requireme... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:df99c56962afa62839f23cc7","quotes":["In addition, we selected another cohort consisting of 38 ESCC patients recei... | [
"CLM:df99c56962afa62839f23cc7",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:e31de79de3077022a039066c"
] | [] | [] | {"qa_id":"QA:dd7ad13a56fc2fda239fc839","qa_group_id":"QAG:a7f097c876c56340661c7940","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Moreover, the transwell assay revealed knockdown of CD73 in two ES... |
QA:e04f892fd5928390f4f0cc7b | QAG:661b6d6f8d1a81b2e285c1a1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "showed that PD‐1/PD‐L1based immune checkpoint inhibitors decreased CPS ≥10 ESCC patients compared with chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage w... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:50b625ebc480e5f41fca81c1","quotes":["22 , 23 , 24 , 25 A meta‐analysis by Leone et al. showed that PD‐1/PD‐L1base... | [
"CLM:50b625ebc480e5f41fca81c1",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:e9c661602207533cf65fed7a"
] | [] | [] | {"qa_id":"QA:e04f892fd5928390f4f0cc7b","qa_group_id":"QAG:661b6d6f8d1a81b2e285c1a1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"showed that PD‐1/PD‐L1based immune checkpoint inhibitors decreased... |
QA:e2ab29aabcfab9a7ed79c643 | QAG:5bae133953b31219c2bf21eb | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Immunotherapy, with agents such as immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive T-cell therapy, has recently increased hope for improved survival outcomes in patients with esophageal cancer ( 4 – 7 )"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:abb01e3e354a91216ac59698","quotes":["Immunotherapy, with agents such as immune checkpoint inhibitors (ICIs), canc... | [
"CLM:abb01e3e354a91216ac59698",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8724211"
] | [
"SPAN:37f14215d0176fb3050d553e"
] | [] | [] | {"qa_id":"QA:e2ab29aabcfab9a7ed79c643","qa_group_id":"QAG:5bae133953b31219c2bf21eb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Immunotherapy, with agents such as immune checkpoint inhibitors (I... |
QA:e3330787d8c18f24e6480cd2 | QAG:2890c9263cf6815e0390333b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Table 3 Pooled incidence rates of adverse events in ESCC patients who received chemo-immunotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:79257d14845eb88760d4ab03","quotes":["Table 3 Pooled incidence rates of adverse events in ESCC patients who receiv... | [
"CLM:79257d14845eb88760d4ab03",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:a14eca4cb564ec7326571d0e"
] | [] | [] | {"qa_id":"QA:e3330787d8c18f24e6480cd2","qa_group_id":"QAG:2890c9263cf6815e0390333b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Table 3 Pooled incidence rates of adverse events in ESCC patients ... |
QA:e42fa03ffae8a55e1900ca4d | QAG:e677088fbd6d3544fcedd731 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Background Immunotherapy has largely improved clinical outcome of patients with esophageal squamous cell carcinoma (ESCC)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pas... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8ce5e2e9da6cba1a7de8b2f9","quotes":["Background Immunotherapy has largely improved clinical outcome of patients w... | [
"CLM:8ce5e2e9da6cba1a7de8b2f9",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10992089"
] | [
"SPAN:87310442dfc77164c8c3673d"
] | [] | [] | {"qa_id":"QA:e42fa03ffae8a55e1900ca4d","qa_group_id":"QAG:e677088fbd6d3544fcedd731","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Background Immunotherapy has largely improved clinical outcome of ... |
QA:e458fa96782f1e52927d82a5 | QAG:048d30792082256f5ee81a4b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For resectable or potentially resectable locally advanced ESCC, the current treatment paradigm established by the CROSS study and the NEOCRTEC5010 study is neoadjuvant chemoradiotherapy followed by surgery, which has achieved a pathologic complete response (pCR) rate o... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7b09ceed1a23b60e1fa2444c","quotes":["For resectable or potentially resectable locally advanced ESCC, the current ... | [
"CLM:7b09ceed1a23b60e1fa2444c",
"CLM:2a0dc33e26036765ea69bb10"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:534cee3df5e2cc61c9ca4b20"
] | [] | [] | {"qa_id":"QA:e458fa96782f1e52927d82a5","qa_group_id":"QAG:048d30792082256f5ee81a4b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For resectable or potentially resectable locally advanced ESCC, th... |
QA:e8ad120f0264aae87121d86d | QAG:60e55878e025f8abd5b3dbba | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Results A total of 66 patients with locally advanced ESCC were included in this study, including 8 patients with stage II, 29 patients with stage III, and 29 patients with stage IVA"? Return the original wording with paper, Claim, and Evidence Span references.
Integra... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5e27c3809de7ce5c43215d53","quotes":["Results A total of 66 patients with locally advanced ESCC were included in t... | [
"CLM:5e27c3809de7ce5c43215d53",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:e2e42ce38b73792731af90c9"
] | [] | [] | {"qa_id":"QA:e8ad120f0264aae87121d86d","qa_group_id":"QAG:60e55878e025f8abd5b3dbba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Results A total of 66 patients with locally advanced ESCC were inc... |
QA:e8d5e4e5e0cc4596fd5c4939 | QAG:68dc562d1ca248464ec9b2d3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In the CheckMate 648 study, the PD-L1 status was associated with the efficacy of ICIs in ESCC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Cl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9d4b88929eb1003dff2d66ba","quotes":["In the CheckMate 648 study, the PD-L1 status was associated with the efficac... | [
"CLM:9d4b88929eb1003dff2d66ba",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9599230"
] | [
"SPAN:ece1001dc22c50ea3e3d937b"
] | [] | [] | {"qa_id":"QA:e8d5e4e5e0cc4596fd5c4939","qa_group_id":"QAG:68dc562d1ca248464ec9b2d3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In the CheckMate 648 study, the PD-L1 status was associated with t... |
QA:ed5a4742553c55d5589c1400 | QAG:2e051f6358475d498faea47f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A nomogram was established to predict pCR according to the independent predictors (cTNM and IINS) identified in the multivariate logistic regression analyses for patients with LA-ESCC who received nICT ( Figure 7A )"? Return the original wording with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:aa4f5863b881fca29d410abc","quotes":["A nomogram was established to predict pCR according to the independent predi... | [
"CLM:aa4f5863b881fca29d410abc",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:06851112729b766997406b43"
] | [] | [] | {"qa_id":"QA:ed5a4742553c55d5589c1400","qa_group_id":"QAG:2e051f6358475d498faea47f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A nomogram was established to predict pCR according to the indepen... |
QA:eef10e64f3ac6d66c264fd67 | QAG:681cf341eb8837f66612278f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "This is a retrospective study to assess neoadjuvant camrelizumab plus chemotherapy for locally advanced ESCC patients, which achieved a promising MPR rate of 50.0%, a pCR rate of 35.3%, and the R0 resection rate of 94.1%"? Return the original wording with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ad11e09b8514e3713f2b5f28","quotes":["This is a retrospective study to assess neoadjuvant camrelizumab plus chemot... | [
"CLM:ad11e09b8514e3713f2b5f28",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9251418"
] | [
"SPAN:6f064298fc738f222e1de75b"
] | [] | [] | {"qa_id":"QA:eef10e64f3ac6d66c264fd67","qa_group_id":"QAG:681cf341eb8837f66612278f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"This is a retrospective study to assess neoadjuvant camrelizumab p... |
QA:f1308daab6b83df9359751f4 | QAG:f8130448a1244da2b40bfe97 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We also enrolled patients with ESCC who received ICBs (including pembrolizumab and nivolumab) as second-line and later-line treatment in our institute between July 2020 and June 2021. Thirty-eight patients with ESCC were present in this cohort"? Return the original wor... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6e88d02645ad4ab7ec6931fc","quotes":["We also enrolled patients with ESCC who received ICBs (including pembrolizum... | [
"CLM:6e88d02645ad4ab7ec6931fc",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:4e3867f603cf3483249e1151"
] | [] | [] | {"qa_id":"QA:f1308daab6b83df9359751f4","qa_group_id":"QAG:f8130448a1244da2b40bfe97","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We also enrolled patients with ESCC who received ICBs (including p... |
QA:f2ece38053cbdb4018033353 | QAG:b7e65a2e807c38648d1ae36e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "compared surgery after chemoradiotherapy to surgery alone in patients with esophageal cancer and found that preoperative chemoradiotherapy improved the survival of patients with potentially resectable esophageal cancer ( 10 )"? Return the original wording with paper, C... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:08a48a247c9286d56048a968","quotes":["And adjuvant treatment has been demonstrated to reduce the postoperative rec... | [
"CLM:08a48a247c9286d56048a968",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:d113d4905922f398548c1a8c"
] | [] | [] | {"qa_id":"QA:f2ece38053cbdb4018033353","qa_group_id":"QAG:b7e65a2e807c38648d1ae36e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"compared surgery after chemoradiotherapy to surgery alone in patie... |
QA:f3f8d006b6dd566ded37064e | QAG:39a0c8cab8576e34ad5a6fed | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "[ 26b ] Here, we found that ATRA inhibited ESCC tumor initiation and progression by promoting OTUD6B translation and inhibiting TIC properties of ESCC cancer cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cfc1021db89b304b25a0e3da","quotes":["ATRA has been reported for its function in treating acute promyelocytic leuk... | [
"CLM:cfc1021db89b304b25a0e3da",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:da9d3fb412f12a123678ef34"
] | [] | [] | {"qa_id":"QA:f3f8d006b6dd566ded37064e","qa_group_id":"QAG:39a0c8cab8576e34ad5a6fed","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"[ 26b ] Here, we found that ATRA inhibited ESCC tumor initiation a... |
QA:f412b50c333400b180f1b676 | QAG:36245e3fa05297703b5b2982 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Recently, the use of immunotherapy in esophageal cancer has been increasingly promoted from second-line to first-line treatment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporti... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f7c9d5bf1ccdd05e69aae4d9","quotes":["Recently, the use of immunotherapy in esophageal cancer has been increasingl... | [
"CLM:f7c9d5bf1ccdd05e69aae4d9",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10714592"
] | [
"SPAN:185e4803f79e433ce003af79"
] | [] | [] | {"qa_id":"QA:f412b50c333400b180f1b676","qa_group_id":"QAG:36245e3fa05297703b5b2982","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Recently, the use of immunotherapy in esophageal cancer has been i... |
QA:f4927ce2ccb74818beb03df0 | QAG:31e14fdc19a8e7a359a79b7f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Moreover, only OTUD6B but no other OTU family members was able to regulate β ‐TrCP, since knock down OTUD6A or OTUD2 did not improve β ‐TrCP protein level in ESCC cells (Figure S1E–H , Supporting Information)"? Return the original wording with paper, Claim, and Evidenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9c73cda88824e22c589117e1","quotes":["Moreover, only OTUD6B but no other OTU family members was able to regulate β... | [
"CLM:9c73cda88824e22c589117e1",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:c2e7de2ee6c132cc4aadf16f"
] | [] | [] | {"qa_id":"QA:f4927ce2ccb74818beb03df0","qa_group_id":"QAG:31e14fdc19a8e7a359a79b7f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Moreover, only OTUD6B but no other OTU family members was able to ... |
QA:f591abc155d968e58a88d106 | QAG:3f5e26367c343c69faa0a333 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In a phase III study of advanced esophageal cancer, KEYNOTE-181, patients with CPS ≥ 10 who received pembrolizumab had a better response rate and OS compared to those who received chemotherapy"? Return the original wording with paper, Claim, and Evidence Span reference... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:425974891808dce8b8d00e8e","quotes":["In a phase III study of advanced esophageal cancer, KEYNOTE-181, patients wi... | [
"CLM:425974891808dce8b8d00e8e",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:a3b22a554f92238d551cc368"
] | [] | [] | {"qa_id":"QA:f591abc155d968e58a88d106","qa_group_id":"QAG:3f5e26367c343c69faa0a333","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In a phase III study of advanced esophageal cancer, KEYNOTE-181, p... |
QA:f59c456afdf0e3c5da86dd7f | QAG:bd049f0889f650078c8f3fe7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The meta‐analysis showed that immunochemotherapy decreased the overall risk of death by 32% and the risk of disease progression or death by 38% in advanced ESCC patients compared with chemotherapy (OS: HR = 0.68, 95% CI 0.61–0.75; PFS: HR = 0.62, 95% CI 0.55–0.70, resp... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:566e53b2b4c06981d3943b35","quotes":["The meta‐analysis showed that immunochemotherapy reduced the overall risk of... | [
"CLM:566e53b2b4c06981d3943b35",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:d9c2e90b6fe3e55400194bf4"
] | [] | [] | {"qa_id":"QA:f59c456afdf0e3c5da86dd7f","qa_group_id":"QAG:bd049f0889f650078c8f3fe7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The meta‐analysis showed that immunochemotherapy decreased the ove... |
QA:f5afb33679bc5d5bcd21e0ad | QAG:ef6ede0cb602a4bf26d79581 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "These results suggested that ICI as second- or later-line treatment for patients with locally advanced or metastatic ESCC was associated with an increased risk of response compared with chemotherapy"? Return the original wording with paper, Claim, and Evidence Span ref... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8cbc0ff5726c04a7d21e1cfe","quotes":["These results suggested that ICI as second- or later-line treatment for pati... | [
"CLM:8cbc0ff5726c04a7d21e1cfe",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8724211"
] | [
"SPAN:a89f9a49224c567aa446bee1"
] | [] | [] | {"qa_id":"QA:f5afb33679bc5d5bcd21e0ad","qa_group_id":"QAG:ef6ede0cb602a4bf26d79581","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"These results suggested that ICI as second- or later-line treatmen... |
QA:f76b638b21f6ce812bf50399 | QAG:ec3fcdea557b15f8369473fa | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "According to the inclusion and exclusion criteria, 453 patients diagnosed with locally advanced ESCC from March 2013 to April 2021 were enrolled of whom 48 patients were in the nCT+ICIs group, and 405 patients were in the nCT group"? Return the original wording with pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0313c682e9e59efb742366b7","quotes":["According to the inclusion and exclusion criteria, 453 patients diagnosed wi... | [
"CLM:0313c682e9e59efb742366b7",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9585292"
] | [
"SPAN:7046e2bb6a629a502ff3f12c"
] | [] | [] | {"qa_id":"QA:f76b638b21f6ce812bf50399","qa_group_id":"QAG:ec3fcdea557b15f8369473fa","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"According to the inclusion and exclusion criteria, 453 patients di... |
QA:f77216347a2aacf3cd510512 | QAG:284458783202d346947d6f82 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "2%) patients achieved pCR, the MPR rate was 62.5%, the clinical downstaging rate was 83.3%, pathological downstaging was achieved in 74.0% of patients, and 1-year DFS rate was 95.2%"? Return the original wording with paper, Claim, and Evidence Span references.
Integra... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:76287602e1565b9f4401c7cf","quotes":["In the present study, neoadjuvant sintilimab plus chemotherapy in patients w... | [
"CLM:76287602e1565b9f4401c7cf",
"CLM:2a0dc33e26036765ea69bb10"
] | [
"PMCID:PMC9098952"
] | [
"SPAN:2e842f6306c6c5e676c93097"
] | [] | [] | {"qa_id":"QA:f77216347a2aacf3cd510512","qa_group_id":"QAG:284458783202d346947d6f82","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"2%) patients achieved pCR, the MPR rate was 62.5%, the clinical do... |
QA:f7d5efd9c08e947282b4e703 | QAG:f0ccbcfc0d84f2b7b7c568ab | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In this study, we aims to evaluate the potential predictive value of CT-derived radiomics in advanced ESCC patients receiving immune-checkpoint inhibitor plus chemotherapy (ICI + CT)"? Return the original wording with paper, Claim, and Evidence Span references.
Integr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0ea450c7cc5fd215e0694270","quotes":["In this study, we aimed to evaluate the potential predictive value of CT-der... | [
"CLM:0ea450c7cc5fd215e0694270",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8557514"
] | [
"SPAN:826d84be50492b48d9ea0e8c"
] | [] | [] | {"qa_id":"QA:f7d5efd9c08e947282b4e703","qa_group_id":"QAG:f0ccbcfc0d84f2b7b7c568ab","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In this study, we aims to evaluate the potential predictive value ... |
QA:f7fd9f50e3838e850ed1af39 | QAG:397998a5c64a2623d11649f3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "trial participants in the PD-1 inhibitor arm received anti-PD-1 agent only, while participants in the chemotherapy arm were treated with conventional chemotherapy regimen; and the trial used at least three of the following (OS, progression-free survival [PFS], objectiv... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6d8b372feb2f9490a744540e","quotes":["Studies eligible for the analyses satisfied each of the following requiremen... | [
"CLM:6d8b372feb2f9490a744540e",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:947e310371175820538cead3"
] | [] | [] | {"qa_id":"QA:f7fd9f50e3838e850ed1af39","qa_group_id":"QAG:397998a5c64a2623d11649f3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"trial participants in the PD-1 inhibitor arm received anti-PD-1 ag... |
QA:f830698b5a601ac377772307 | QAG:cef61794e1d1f4a9dff36fa1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We have previously reported that the presence of TLSs around gastric cancer was associated with a good prognosis, that increased granzyme B and perforin expression is observed around TLSs, and that memory T cells are present around TLSs"? Return the original wording wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d383437af8ee866436540c2f","quotes":["We have previously reported that the presence of TLSs around gastric cancer ... | [
"CLM:d383437af8ee866436540c2f",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9233387"
] | [
"SPAN:45a2a8f4c82bf35ae7a0103b"
] | [] | [] | {"qa_id":"QA:f830698b5a601ac377772307","qa_group_id":"QAG:cef61794e1d1f4a9dff36fa1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We have previously reported that the presence of TLSs around gastr... |
QA:f83392ae0d6bc9acfc9558c3 | QAG:23ff39f6789013225e5e7fda | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "in the ESCC subgroup, the OS was also improved at 12.6 months v"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references; asse... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a29735543216d0090761d54d","quotes":["In the KEYNOTE-590 trial, pembrolizumab plus chemotherapy exhibited a superi... | [
"CLM:a29735543216d0090761d54d",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10714592"
] | [
"SPAN:f885c3f515417d73270790e1"
] | [] | [] | {"qa_id":"QA:f83392ae0d6bc9acfc9558c3","qa_group_id":"QAG:23ff39f6789013225e5e7fda","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"in the ESCC subgroup, the OS was also improved at 12.6 months v\"?... |
QA:f880a71c8fc5a700a0738de5 | QAG:4420ba8f9fcc36caf9bb6d56 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "119 patients with ESCC who received anti-PD-1 inhibitor treatment from December 2018 to September 2020 in Sun Yat-sen University Cancer Center, Guangzhou were included in this retrospective study"? Return the original wording with paper, Claim, and Evidence Span refere... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:637e88f9f24574c1afdd4b4e","quotes":["119 patients with ESCC who received anti-PD-1 inhibitor treatment from Decem... | [
"CLM:637e88f9f24574c1afdd4b4e",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:203a3dccb0b93fde6413dc53"
] | [] | [] | {"qa_id":"QA:f880a71c8fc5a700a0738de5","qa_group_id":"QAG:4420ba8f9fcc36caf9bb6d56","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"119 patients with ESCC who received anti-PD-1 inhibitor treatment ... |
QA:fa8ac4a24f2834b72bd9b0cb | QAG:a28af26044c0d6e8d0669b09 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Secondly, in this systematic review and meta-analysis, a total of 1651 ESCC patients from 9 studies received anti-PD1 therapy (tislelizumab, toripalimab, pembrolizumab, camrelizumab, sintilimab, and nivolumab) and only 37 patients from 1 study received anti-PD-L1 thera... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ae37f8a84ac7e7a186fb1e35","quotes":["Secondly, in this systematic review and meta-analysis, a total of 1651 ESCC ... | [
"CLM:ae37f8a84ac7e7a186fb1e35",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:0f3aaa826acab02f48654fa0"
] | [] | [] | {"qa_id":"QA:fa8ac4a24f2834b72bd9b0cb","qa_group_id":"QAG:a28af26044c0d6e8d0669b09","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Secondly, in this systematic review and meta-analysis, a total of ... |
QA:fab2fbcd6cf7f8e477d67b5d | QAG:8f7c64c5c23d905c018417c8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Higher doses of neoadjuvant radiation for esophageal cancer did not improve the pathologic complete response rate or survival: a propensity-matched analysis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requiremen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:65ca74e0888d4dadb9030e62","quotes":["Higher doses of neoadjuvant radiation for esophageal cancer do not affect th... | [
"CLM:65ca74e0888d4dadb9030e62",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:5d5956dc6aa67a57eecb06f8"
] | [] | [] | {"qa_id":"QA:fab2fbcd6cf7f8e477d67b5d","qa_group_id":"QAG:8f7c64c5c23d905c018417c8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Higher doses of neoadjuvant radiation for esophageal cancer did no... |
QA:fbca68e14578b4a928a11de1 | QAG:a90d76fb2c2c38d654fefcab | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "5%) patients achieved pCR"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references; assess the embedded target Claim only agai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:53f595b2e5be60ea885f52ca","quotes":["Results Of the 285 enrolled LA-ESCC patients received nICT followed by radic... | [
"CLM:53f595b2e5be60ea885f52ca",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:538b7a39ad4c3d2be43400f4"
] | [] | [] | {"qa_id":"QA:fbca68e14578b4a928a11de1","qa_group_id":"QAG:a90d76fb2c2c38d654fefcab","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"5%) patients achieved pCR\"? Return the original wording with pape... |
QA:fc8f26f5428d483e9654a0c9 | QAG:71700b787e1c5fcf8a970161 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In this study, we aims to evaluate the safety and effectiveness of camrelizumab combined with chemotherapy as a neoadjuvant regimen in the treatment of locally advanced ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prov... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b37b5af0b3513e6f0e521ae1","quotes":["In this study, we aimed to investigate the safety and effectiveness of camre... | [
"CLM:b37b5af0b3513e6f0e521ae1",
"CLM:271ef2ae6ac25da19ecda350"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:b3a6861c582d4f657881973b"
] | [] | [] | {"qa_id":"QA:fc8f26f5428d483e9654a0c9","qa_group_id":"QAG:71700b787e1c5fcf8a970161","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In this study, we aims to evaluate the safety and effectiveness of... |
QA:ff74bf6d44a8b91ad43c2490 | QAG:fe3d0ca3ed747fca61e896ed | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Results Eleven phase 3 randomized controlled trials (RCTs) involving 6267 patients with ESCC were included in this meta-analysis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact support... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:70c34f24958201ce03d2e417","quotes":["Results Eleven phase 3 randomized controlled trials (RCTs) involving 6267 pa... | [
"CLM:70c34f24958201ce03d2e417",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10185849"
] | [
"SPAN:a1a1e85d7919d8bd72a12b9a"
] | [] | [] | {"qa_id":"QA:ff74bf6d44a8b91ad43c2490","qa_group_id":"QAG:fe3d0ca3ed747fca61e896ed","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Results Eleven phase 3 randomized controlled trials (RCTs) involvi... |
QA:ffd0317305b6593968cb689c | QAG:273b885a303d1087f9834ea8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "This retrospective study reviewed the electronic medical records of patients with esophageal cancer who received anlotinib plus PD-1 blockade or anlotinib monotherapy as second or further-line therapy from January 2019 to February 2021 at Henan Cancer Hospital"? Return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2a0dc33e26036765ea69bb10","quotes":["This retrospective study reviewed the electronic medical records of patients... | [
"CLM:2a0dc33e26036765ea69bb10",
"CLM:0313c682e9e59efb742366b7"
] | [
"PMCID:PMC9428701"
] | [
"SPAN:e5eb219f30f6b11e84fc5430"
] | [] | [] | {"qa_id":"QA:ffd0317305b6593968cb689c","qa_group_id":"QAG:273b885a303d1087f9834ea8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"This retrospective study reviewed the electronic medical records o... |
QA:fff4341b1315a318e24ca524 | QAG:1cdf0edae883f5fdc9216b7b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Meta-analysis of three RCTs comprising 1268 patients revealed that ICI treatment improved median OS compared with chemotherapy when used as second- or later-line treatment of locally advanced or metastatic ESCC"? Return the original wording with paper, Claim, and Evide... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:155fac513205cdf17803defe","quotes":["Meta-analysis of three RCTs comprising 1268 patients revealed that ICI treat... | [
"CLM:155fac513205cdf17803defe",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8724211"
] | [
"SPAN:65d761af5474c4cb7707caba"
] | [] | [] | {"qa_id":"QA:fff4341b1315a318e24ca524","qa_group_id":"QAG:1cdf0edae883f5fdc9216b7b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Meta-analysis of three RCTs comprising 1268 patients revealed that... |
QA:02b06f0199d9335b11208da1 | QAG:2710405ba7cb6bf6a6b517a0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Targeting VEGFR2 with ramucirumab increased PD-L1 expression and CD8+ T cell infiltration in the tumor microenvironment of patients with advanced gastric cancer and reduced the frequency of immunosuppressive effector regulatory T cells in tumor-infiltrating lymphocytes... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:878f99c401450b2636afba6b","quotes":["Targeting VEGFR2 with ramucirumab increased PD-L1 expression and CD8+ T cell... | [
"CLM:878f99c401450b2636afba6b",
"CLM:072282e1a03a6f258ddcaf17"
] | [
"PMCID:PMC7602637"
] | [
"SPAN:b3216ec6699fe62239253b11"
] | [] | [] | {"qa_id":"QA:02b06f0199d9335b11208da1","qa_group_id":"QAG:2710405ba7cb6bf6a6b517a0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Targeting VEGFR2 with ramucirumab increased PD-L1 expression and C... |
QA:02f1a17b55e30a924502eabf | QAG:4bd14e0f44ec4884e7639988 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10613141? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10613141","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10613141"
] | [] | [] | [] | {"qa_id":"QA:02f1a17b55e30a924502eabf","qa_group_id":"QAG:4bd14e0f44ec4884e7639988","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1061314... |
QA:0921404391af8d7da2cbab1f | QAG:0c6c7c4b733aa48107fbcab7 | provenance_qa | paper_evidence_availability | provenance_qa | G024 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9357620? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9357620","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9357620"
] | [] | [] | [] | {"qa_id":"QA:0921404391af8d7da2cbab1f","qa_group_id":"QAG:0c6c7c4b733aa48107fbcab7","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G024","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9357620... |
QA:0dc4e52d7009359f257eb2f4 | QAG:005e51b1d004b1bd959dabd3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "suggested that treating esophageal or G/GEJ cancer with PD-1/PD-L1 inhibitors led to a higher pooled hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS), indicating their ineffectiveness"? Return the original wording with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:072282e1a03a6f258ddcaf17","quotes":["A meta-analysis conducted by Wang et al. [ 8 ] sugg... | [
"CLM:072282e1a03a6f258ddcaf17",
"CLM:03ccfa8216f57bebab8dab3a",
"CLM:6ee7ab0c2b485e3cec13aff8"
] | [
"PMCID:PMC8397221",
"PMCID:PMC7602637"
] | [
"SPAN:b090b5b651896cb19b6ff8b3",
"SPAN:0ab3c196ce00c5481ec81caa"
] | [
"ASC2:3bd33acc30cde3d844aa36e3"
] | [
"HYP:DCH:bad022e9565efb8163a44707"
] | {"qa_id":"QA:0dc4e52d7009359f257eb2f4","qa_group_id":"QAG:005e51b1d004b1bd959dabd3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"suggested that treating esophageal or G/GEJ cancer with PD-1/PD-L1... |
QA:0f234b4a7d4194314c4dcc12 | QAG:2a164a0fe31e86e021e1c15b | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "In a phase 2 study of G/GEJ cancer patients who received ≥ 2 lines of prior therapy, targeting the PD-1 receptor with pembrolizumab benefited a minority of patients, with approximately 80% of patients rapidly progressing, and a response rate of 15.5% in patients with P... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9285985a5af7933bbecaa2c4","quotes":["In a phase 2 study of G/GEJ cancer patients who received ≥ 2 lines of prior ... | [
"CLM:9285985a5af7933bbecaa2c4",
"CLM:5de3f7118846b520e68dd9bf"
] | [
"PMCID:PMC7602637"
] | [
"SPAN:a52f0c6290747f879259dbb3"
] | [] | [] | {"qa_id":"QA:0f234b4a7d4194314c4dcc12","qa_group_id":"QAG:2a164a0fe31e86e021e1c15b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"In a phase 2 study of G/GEJ cancer patients who received ≥ 2 lines... |
QA:11032792c9626927ad5e57d3 | QAG:50c3d603a1b6c465ca49fd16 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "In the present study, we conducted a 2-cohort phase 2 trial in which cohort 1 aims to evaluate the antitumor activity and safety of HX008 plus irinotecan as second-line treatment in patients with advance G/GEJ cancer"? Return the original wording with paper, Claim, and... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c71b11d5fa482ce5b985c667","quotes":["In the present study, we conducted a 2-cohort phase 2 trial in which cohort ... | [
"CLM:c71b11d5fa482ce5b985c667",
"CLM:32fd278c95b64d239d4e1a49"
] | [
"PMCID:PMC7566427"
] | [
"SPAN:d8523627d3c2647a94178f0c"
] | [] | [] | {"qa_id":"QA:11032792c9626927ad5e57d3","qa_group_id":"QAG:50c3d603a1b6c465ca49fd16","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"In the present study, we conducted a 2-cohort phase 2 trial in whi... |
QA:17ad01938362a9428f725422 | QAG:89900015a5dcce94338baf1d | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Ramucirumab demonstrated antitumor activity and a favorable safety profile, which led to its approval in several indications, including second-line advanced G/GEJ cancer as single agent and in combination with paclitaxel"? Return the original wording with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9101e1935c3e1afe70e5e8d5","quotes":["Ramucirumab demonstrated a... | [
"CLM:9101e1935c3e1afe70e5e8d5",
"CLM:3add2a9d54141ff5edee4d18",
"CLM:07188d589c90a9f6b66a8e97",
"CLM:619cf140fcdd7c535b17a748"
] | [
"PMCID:PMC7602637",
"PMCID:PMC6386029",
"PMCID:PMC7781732"
] | [
"SPAN:1d228c1c957dbe15dd5100b1",
"SPAN:413f601150ed9386bc71b8ec",
"SPAN:4ae33b94f6a1c28552744dd4"
] | [
"ASC2:0f2e011441ef90694f7c1e4d",
"ASC2:286c6e807bec7aa05b904164",
"ASC2:4538ac9f5c8c8bdc796884c8"
] | [
"HYP:DCH:4bee2cb72836544b4b9eda23",
"HYP:DCH:e8df957b97babb3c84969240"
] | {"qa_id":"QA:17ad01938362a9428f725422","qa_group_id":"QAG:89900015a5dcce94338baf1d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Ramucirumab demonstrated antitumor activity and a favorable safety... |
QA:1e125ebf7faf2d09a9402c0f | QAG:75d5f24b38fe6ae12548d32d | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "The randomized, open-label, phase 3 KEYNOTE-061 trial aims to evaluate the efficacy and safety of pembrolizumab versus paclitaxel as second-line therapy in patients with advanced G/GEJ cancer that progressed on platinum and fluoropyrimidine-based chemotherapy"? Return ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b48cdd8015adee1a3c98cb91","quotes":["The randomized, open-label, phase 3 KEYNOTE-061 trial was designed to evalua... | [
"CLM:b48cdd8015adee1a3c98cb91",
"CLM:3dd0f0d29cb356f9a00a37ce"
] | [
"PMCID:PMC10314681"
] | [
"SPAN:ae2a73fa78b64e130dd36ce6"
] | [] | [] | {"qa_id":"QA:1e125ebf7faf2d09a9402c0f","qa_group_id":"QAG:75d5f24b38fe6ae12548d32d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"The randomized, open-label, phase 3 KEYNOTE-061 trial aims to eval... |
QA:1fe976fac52ab673c6643bb9 | QAG:4d8d87d683ee0166dc784eee | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "gov, NCT03745-170) showed that CapeOX combined with sintilimab improved the prognosis of all unresectable advanced gastric cancer patients in first-line therapy regardless of the expression of PD-L1"? Return the original wording with paper, Claim, and Evidence Span ref... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d1ca67e9969fc8e3a2af4dd7","quotes":["On the other hand, the ORIENT-16 trial (ClinicalTrials.gov, NCT03745-170) sh... | [
"CLM:d1ca67e9969fc8e3a2af4dd7",
"CLM:07188d589c90a9f6b66a8e97"
] | [
"PMCID:PMC9491115"
] | [
"SPAN:e410b04868eb51503637f59a"
] | [] | [] | {"qa_id":"QA:1fe976fac52ab673c6643bb9","qa_group_id":"QAG:4d8d87d683ee0166dc784eee","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"gov, NCT03745-170) showed that CapeOX combined with sintilimab imp... |
QA:25663562e633fdd0c0053880 | QAG:4d2bd3cd2d520ac2f94b67c2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Conclusions Nivolumab treatment led to clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b18a30d65b19c982dd0c424c","quotes":["Conclusions Nivolumab treatment resulted in clinically meaningful long-term ... | [
"CLM:b18a30d65b19c982dd0c424c",
"CLM:03ccfa8216f57bebab8dab3a"
] | [
"PMCID:PMC7165140"
] | [
"SPAN:d7ae4a6128409fbdc8bb153e"
] | [] | [] | {"qa_id":"QA:25663562e633fdd0c0053880","qa_group_id":"QAG:4d2bd3cd2d520ac2f94b67c2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Conclusions Nivolumab treatment led to clinically meaningful long-... |
QA:29713aed37fa1d67314a19a6 | QAG:f2bed9311e862902b560878d | provenance_qa | exact_evidence_retrieval | provenance_qa | G024 | en | train | Which exact source passage supports the statement "Conclusions and relevance Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment"? Return the original wording with ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dbbcc9e09339a0079c59d807","quotes":["Conclusions and relevance Pembrolizumab monotherapy demonstrated promising a... | [
"CLM:dbbcc9e09339a0079c59d807",
"CLM:07188d589c90a9f6b66a8e97"
] | [
"PMCID:PMC5885175"
] | [
"SPAN:6e8aaab5860d7a34599b6098"
] | [] | [] | {"qa_id":"QA:29713aed37fa1d67314a19a6","qa_group_id":"QAG:f2bed9311e862902b560878d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G024","question":"Which exact source passage supports the statement \"Conclusions and relevance Pembrolizumab monotherapy demonstrated p... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.